Chao Yuan Li Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chao Yuan Li Cai has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Abigail Rai
Acute Medical Unit (AMU), Impur Christian Hospital, Mokokchung, IND
1 shared publication- Alberto Ramirez
Department of Radiology, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Madrid, Spain
1 shared publication - Ana Royuela
Biostatistics Unit, Biomedical Research Institute (IDIPHISA), CIBERESP, Puerta de Hierro University Hospital, Madrid, Spain
1 shared publication Bendangjungla Pongen
Emergency Medicine, Bethesda Hospital, Kohima, IND
1 shared publicationGaurav Pratap Singh
Critical Care Medicine, King's College Hospital NHS Foundation Trust, London, GBR
1 shared publicationHariharasudhan Balaji
Emergency Medicine, Southern Health and Social Care Trust, Armagh, GBR
1 shared publication
Latest Publications
- Open Access
- 5 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11)
Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis
Type 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing the need for therapies that extend benefits beyond glycemic control. Injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated both cardioprotective and renoprotective potential, but the comparative efficacy of individual agents remains uncertain. This network meta-analysis (NMA) evaluated and ranked the effects of GLP-1 RAs on major adverse cardiovascular events (MACE) and renal composite outcomes, both prespecified as co-primary endpoints. A systematic search of PubMed, Scopus, ScienceDirect, Web of Science, and the Cochrane Library was conducted from inception to January 2024. Eligible randomized controlled trials enrolled adults with T2DM, including those with or without established cardiovascular disease or chronic kidney disease. Renal composite outcomes were defined as a decline in estimated glomerular filtration rate (eGFR) and/or onset of macroalbuminuria. Direct and indirect evidence were synthesized using a frequentist NMA framework to generate odds ratios (ORs) with 95% confidence intervals (CIs), while treatment hierarchy was assessed with Surface Under the Cumulative Ranking Curve (SUCRA) values. Transitivity and consistency assumptions were tested and satisfied, and the risk of bias was assessed with the Cochrane RoB2 tool. Fifteen randomized trials involving a pooled sample of more than 90,000 participants were included. Efpeglenatide ranked highest for both MACE (OR: 0.74; 95% CI: 0.62-0.87; SUCRA: 81.5%) and renal outcomes (OR: 0.68; 95% CI: 0.57-0.81; SUCRA: 81.33%), underscoring its clinical significance over other effective agents such as albiglutide and semaglutide. Albiglutide, semaglutide, dulaglutide, and liraglutide also provided significant benefits, albeit with lower rankings. No major inconsistency or publication bias was detected. In conclusion, this NMA reinforces the class-wide cardiorenal benefits of GLP-1 receptor agonists while emphasizing variations in efficacy among individual agents, the limited evidence base for certain drugs, and the need for future head-to-head trials specifically designed to evaluate cardiovascular and renal endpoints.
- 5 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11)
Open AccessCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis
Type 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing the need for therapies that extend benefits beyond glycemic control. Injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated both cardioprotective and renoprotective potential, but the comparative efficacy of individual agents remains uncertain. This network meta-analysis (NMA) evaluated and ranked the effects of GLP-1 RAs on major adverse cardiovascular events (MACE) and renal composite outcomes, both prespecified as co-primary endpoints. A systematic search of PubMed, Scopus, ScienceDirect, Web of Science, and the Cochrane Library was conducted from inception to January 2024. Eligible randomized controlled trials enrolled adults with T2DM, including those with or without established cardiovascular disease or chronic kidney disease. Renal composite outcomes were defined as a decline in estimated glomerular filtration rate (eGFR) and/or onset of macroalbuminuria. Direct and indirect evidence were synthesized using a frequentist NMA framework to generate odds ratios (ORs) with 95% confidence intervals (CIs), while treatment hierarchy was assessed with Surface Under the Cumulative Ranking Curve (SUCRA) values. Transitivity and consistency assumptions were tested and satisfied, and the risk of bias was assessed with the Cochrane RoB2 tool. Fifteen randomized trials involving a pooled sample of more than 90,000 participants were included. Efpeglenatide ranked highest for both MACE (OR: 0.74; 95% CI: 0.62-0.87; SUCRA: 81.5%) and renal outcomes (OR: 0.68; 95% CI: 0.57-0.81; SUCRA: 81.33%), underscoring its clinical significance over other effective agents such as albiglutide and semaglutide. Albiglutide, semaglutide, dulaglutide, and liraglutide also provided significant benefits, albeit with lower rankings. No major inconsistency or publication bias was detected. In conclusion, this NMA reinforces the class-wide cardiorenal benefits of GLP-1 receptor agonists while emphasizing variations in efficacy among individual agents, the limited evidence base for certain drugs, and the need for future head-to-head trials specifically designed to evaluate cardiovascular and renal endpoints.
- Open Access
- 8 February 2025
- Published by MDPI AG in Journal of Imaging
- Vol. 11 (2) , 47
Differentiation of Atypical Lipomatous Tumors from Lipomas: Our Experience with Visual Analysis of Conventional Magnetic Resonance Imaging
Differentiating atypical lipomatous tumors (ALTs) from lipomas using imaging techniques is a challenge, and the biopsy with immunohistochemical determination of murine double minute 2 (MDM2) oncogene is the gold standard. We are looking for a management algorithm with the visual analysis of magnetic resonance images in these two fatty soft tissue tumors that allow us to avoid some biopsies. Two radiologists, blinded to the final diagnosis, independently assessed various features on conventional magnetic resonance imaging (MRI), in 79 patients with pathologically confirmed fatty tumors as either lipoma (MDM2 negative) or ALT (MDM2 positive). Results: The interobserver agreement for the most MRI features was moderate and the musculoskeletal radiologist accuracy for final diagnosis was 90% sensitivity and 66% specificity. Tumors with homogeneous fat signals and a maximum size < 8 cm were always lipomas (p < 0.001), and the tumors with septa thickness ≥ 2 mm, or more than one non-fat nodule, and a maximum size ≥ 12.8 cm were typically ALTs. While those tumors with septa < 2 mm or one non-fat nodule, independently of maximum size, the diagnosis of lipoma versus ALT is uncertain and a biopsy is required.
- 8 February 2025
- Published by MDPI AG in Journal of Imaging
- Vol. 11 (2) , 47
Open AccessDifferentiation of Atypical Lipomatous Tumors from Lipomas: Our Experience with Visual Analysis of Conventional Magnetic Resonance Imaging
Differentiating atypical lipomatous tumors (ALTs) from lipomas using imaging techniques is a challenge, and the biopsy with immunohistochemical determination of murine double minute 2 (MDM2) oncogene is the gold standard. We are looking for a management algorithm with the visual analysis of magnetic resonance images in these two fatty soft tissue tumors that allow us to avoid some biopsies. Two radiologists, blinded to the final diagnosis, independently assessed various features on conventional magnetic resonance imaging (MRI), in 79 patients with pathologically confirmed fatty tumors as either lipoma (MDM2 negative) or ALT (MDM2 positive). Results: The interobserver agreement for the most MRI features was moderate and the musculoskeletal radiologist accuracy for final diagnosis was 90% sensitivity and 66% specificity. Tumors with homogeneous fat signals and a maximum size < 8 cm were always lipomas (p < 0.001), and the tumors with septa thickness ≥ 2 mm, or more than one non-fat nodule, and a maximum size ≥ 12.8 cm were typically ALTs. While those tumors with septa < 2 mm or one non-fat nodule, independently of maximum size, the diagnosis of lipoma versus ALT is uncertain and a biopsy is required.